Keywords: NicOx, Private placement, Financing, Naproxcinod, Osteoarthritis
NicOx raises 30 million-euro in private placements with backing from French govt’s FSI fund; files naproxcinod with FDA
Article | 19 November 2009
French biotechnology firm NicOx has successfully raised 30 million euros ($44.7 million) through a private placement to institutional investors, including 20 million euros ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
